论文部分内容阅读
目的检测Ｐ１６蛋白、多药耐药基因（ＭＤＲ１）及组织纤溶酶原激活物（ｔ－ＰＡ）在乳腺浸润型导管癌组织中的表达及水平，并探讨三者与其他临床病理资料的关系，以便为乳癌的辅助治疗提供更多的信息。方法分别采用免疫组化ＡＢＣ法、ＲＴ－ＰＣＲ方法、化学底物发色法测定Ｐ１６蛋白、ＭＤＲ１、ｔ－ＰＡ值，统计患者的临床分期、病理分级、激素受体、月经状况等，并作相关性分析。结果Ｐ１６蛋白（８９例），阴性和低表达共６７例，阳性仅２２例，表达状况与肿瘤临床分期及病理分级无相关性；ＭＤＲ１（５５例），阳性表达１６例，阴性和低表达共３９例，耐药性在不同的临床分期及激素受体状况组中无差别；ｔ－ＰＡ值在乳癌组（ｎ＝６９）为９８±４７Ｉｕ／ｍｇ蛋白，略高于纤维瘤组（８７±４０，ｎ＝３３），无统计学差别，激素受体（ＥＲ、ＰＲ）双阳性组ｔ－ＰＡ值（１２５±３７）显著高于其他组，随临床分期Ⅰ→Ⅲ，ｔ－ＰＡ值呈显著下降趋势（Ｐ＜０．０１）。结论乳癌组织存在较大比例的Ｐ１６蛋白丢失和低表达（７５．２８％），一定比例的ＭＤＲ１高表达（２９．１％），ｔ－ＰＡ值可作为激素受体的补充说明，并提示临床病程。
Objective To detect the expression and level of P16 protein, multidrug resistance gene (MDR1) and tissue plasminogen activator (t-PA) in invasive ductal carcinoma of breast, and to explore the relationship between the three and other clinicopathological data. In order to provide more information for the adjuvant treatment of breast cancer. Methods The levels of P16 protein, MDR1, and t-PA were measured by immunohistochemical ABC method, RT-PCR method, and chemical substrate chromogenic method. The clinical staging, pathological grade, hormone receptor, and menstrual status of the patients were counted. Correlation analysis. Results P16 protein (89 cases), negative and low expression in a total of 67 cases, only 22 cases of positive, no correlation between the expression status and tumor clinical stage and pathological grade; MDR1 (55 cases), positive expression of 16 cases, negative and low expression In 39 patients, there was no difference in drug resistance between different clinical stages and hormone receptor status groups; the t-PA value in the breast cancer group (n=69) was 98±47Iu/mg protein, slightly higher than the fibroid tumor group (87±). 40,n=33), without statistical difference, t-PA (125±37) in hormone receptor (ER, PR) double positive group was significantly higher than other groups, with clinical stage I → III, t-PA value Significant decline trend (P <0.01). Conclusion There is a large proportion of P16 protein loss and low expression in breast cancer tissues (75.28%), and a certain percentage of MDR1 is highly expressed (29.1%). The t-PA value can be used as a supplementary explanation for hormone receptors and prompt clinical Disease course.